These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37195063)

  • 21. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
    Keystone EC; Curtis JR; Fleischmann RM; Furst DE; Khanna D; Smolen JS; Mease PJ; Schiff MH; Coteur G; Davies O; Combe B
    J Rheumatol; 2011 Jun; 38(6):990-6. PubMed ID: 21362764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
    Kavanaugh A; Smolen JS; Emery P; Purcaru O; Keystone E; Richard L; Strand V; van Vollenhoven RF
    Arthritis Rheum; 2009 Nov; 61(11):1592-600. PubMed ID: 19877104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E; Heijde Dv; Mason D; Landewé R; Vollenhoven RV; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
    Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
    Weinblatt ME; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; VanLunen B; Ecoffet C; Cioffi C; Emery P
    Arthritis Rheumatol; 2017 Oct; 69(10):1937-1948. PubMed ID: 28666080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
    Mease PJ
    Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
    van der Heijde D; Keystone EC; Curtis JR; Landewé RB; Schiff MH; Khanna D; Kvien TK; Ionescu L; Gervitz LM; Davies OR; Luijtens K; Furst DE
    J Rheumatol; 2012 Jul; 39(7):1326-33. PubMed ID: 22589265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
    Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.
    Pfeil A; Nussbaum A; Renz DM; Jung C; Oelzner P; Malich A; Wolf G; Böttcher J
    Rheumatol Int; 2019 Apr; 39(4):637-645. PubMed ID: 30569216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Iwata S; Hanami K; Fukuyo S; Miyagawa I; Yamaguchi A; Kawabe A; Saito K; Tanaka Y
    Arthritis Res Ther; 2021 Jun; 23(1):154. PubMed ID: 34074349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
    Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
    Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
    Burmester G; Nüsslein H; von Hinüber U; Detert J; Richter C; Kumke T; Leunikava I; Lendl U; Fricke D; Müller-Ladner U
    Clin Exp Rheumatol; 2019; 37(5):842-851. PubMed ID: 30873942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E; McKenna F; Vencovsky J; Valente R; Goel N; Vanlunen B; Davies O; Stahl HD; Alten R
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
    Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
    Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study.
    López-Medina C; Calvo-Gutiérrez J; Ábalos-Aguilera MC; Cepas F; Plasencia-Rodríguez C; Martínez-Feito A; Balsa A; Faré-García R; Juan-Mas A; Ruiz-Esquide V; Sainz L; Díaz-Torné C; Godoy-Navarrete FJ; Añón-Oñate I; Mena-Vázquez N; Manrique-Arija S; Moreno-García MS; Ortega-Castro R; Escudero-Contreras A
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38395455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.